PD-L1 expression on circulating tumour cells (CTCs) in advanced melanoma appears to be predictive of patient response to pembrolizumab and an independent biomarker of progression-free survival, Australian research shows. A small WA study of 40 patients commencing on pembrolizumab therapy for mostly first and second line therapy was able to detect CTCs in 63% of ...
Liquid biopsy CTCs predicts response to pembrolizumab in melanoma
By Mardi Chapman
18 Mar 2020